Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination

Vaccine

Volumn 16, Issue 7, 1998, Pages 727-731

  Lanza, Paola ^a   Moss, Ronald B ^a   Giermakowska, Wieslawa ^a   Hancock, Richard B ^a   Richieri, Steven P ^a   Theofa, Georgia ^a   Jensen, Fred C ^a   Salk, Peter L ^b   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Adjuvant; Dose; HIV 1; Immunization

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

AIDS VACCINES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FREUND'S ADJUVANT; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-4; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; MICE, INBRED C57BL; VACCINES, INACTIVATED;

EID: 0032053639     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00256-9     Document Type: Article

References (17)

1. 1 Haynes, B.F., Pantaleo, G. and Fauci, A.S. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996, 271, 324-328.
2. 2 Shearer, G.M. and Clerici, M. Protective immunity against HIV infection: has nature done the experiment for us?. Immunology Today 1996, 17, 21-24.
3. + T cells. Science 1995, 270, 1811-1815.
4. 4 Paxton, W.A., Martin, S.R. and Tse, D. et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. 1996, 2, 412-417.
5. 5 Salk, J., Bretscher, P.A., Salk. P., Clerici, M. and Shearer, G.M. A strategy for prophylactic vaccination against HIV. Science 1993, 260, 1270-1272.
6. 6 Salk, P.L. and Salk, J. Cell-mediated immunologic memory in prevention and treatment of HIV disease. Res. Immunol. 1994, 145, 629-635.
7. 7 Stott, E.J., Chan, W.L. and Mills, K.H. et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990, 336, 1538-1541.
8. 8 Hirsch, V.M., Goldstein, S. and Hynes, N.A. et al. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J. Infect. Dis. 1994, 170, 51-59.
9. 9 Vaslin, B., Le Grand, R. and Vogt, G. et al. Induction of humoral and cellular immunity to simian immunodeficiency virus: what are the requirements for protection?. Vaccine 1994, 12, 1132-1140.
10. 10 Willet, B.J., Flynn, J.N. and Hosie, M.J. FIV infection of the domestic cat: an animal model for AIDS. Immunol. Today 1997, 18, 182-189.
11. 11 Trauger, R.J., Ferre, F. and Daigle, A.E. et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency v-rus type-1 (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J. Infect. Dis. 1994, 169, 1256-1264.
12. 12 Maggi, E., Manetti, R. and Annunziato, F. et al. Functional characterization and modulation of cytokine production by CDS+ T cells from human immunodeficiency virus-infected individuals. Blood 1997, 89, 3672-3681.
13. 13 Lehner, T., Wang, Y. and Cranage, M. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med. 1996, 2, 767-775.
14. 14 Furchi, L., Scarlatti, G. and Burastero, S. et al. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4+ T cells from exposed uninfected individuals expressing the wildtype CCR-5 Allele. J. Exp. Med. 1997, 186, 455-460.
15. 15 Mitchell, M.S. et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988, 48, 5883-5893.
16. 16 Mitchell, M.S. et al. Active-specific immunotherapy for melanoma. J. Clin. Oncol. 1990, 8, 856-869.
17. 17 Mitchell et al. A randomized Phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can. J. Infect. Dis. 1995, 6(Suppl C, abstract 2027). In: Abstracts and Final Program of the 19th International Congress of Chemotherapy, July 1995, Montreal, Quebec, Canada.